Researchers have identified a crucial molecular trigger that may explain why the brain’s immune system becomes dangerously overactive in Alzheimer’s disease, opening the door to a new class of targeted treatments aimed at slowing cognitive decline.
In a new preclinical study published in Cell Chemical Biology, scientists at Scripps Research report that a protein called STING protein acts as a central “switch” driving chronic inflammation in the Alzheimer’s brain. By blocking a specific chemical modification of this protein, the researchers were able to significantly reduce inflammation and protect critical neural connections in experimental models. This discovery builds on growing interest in neuroinflammation as a central driver of disease progression, alongside well-known processes such as amyloid plaque deposition and tau pathology.
The brain normally relies on its own immune defense system, largely mediated by microglial cells, to detect threats and respond rapidly. However, in Alzheimer’s disease, these immune cells remain persistently activated, leading to prolonged inflammation that disrupts communication between neurons and contributes to memory loss and cognitive decline. Increasing evidence suggests that this sustained inflammatory response may play an equally important role as protein aggregation in driving neuronal damage.
The study sheds light on how this damaging cycle begins and persists. Researchers discovered that STING undergoes a chemical process known as S-nitrosylation, in which a nitric oxide related molecule attaches to the protein. This modification locks STING into an overactive state, amplifying inflammatory signals. The team pinpointed the exact site of this change, a single amino acid called cysteine 148. When modified, STING proteins cluster together and trigger a cascade of immune responses. Elevated levels of this altered form, referred to as SNO STING, were found in brain tissue from Alzheimer’s patients, as well as in laboratory grown human brain immune cells and animal models of the disease.
Further experiments revealed that hallmark Alzheimer’s protein aggregates, including amyloid-beta and alpha-synuclein, can themselves trigger this harmful modification. This creates a self-reinforcing cycle in which protein buildup drives inflammation, inflammation increases nitric oxide production, and nitric oxide further activates STING, thereby sustaining ongoing brain injury. Similar inflammatory loops have also been implicated in other neurodegenerative conditions such as Parkinson’s disease, suggesting broader relevance of this pathway.
To test whether interrupting this cycle could be beneficial, researchers engineered a modified version of STING that cannot undergo S-nitrosylation. When introduced into Alzheimer’s mouse models, this altered protein significantly reduced inflammation and helped preserve synapses, the essential connections between neurons responsible for memory and learning. Synaptic loss is widely recognized as one of the strongest correlates of cognitive decline in Alzheimer’s disease, making this finding particularly important.
Protecting these synapses is considered a key strategy for slowing or preventing cognitive deterioration. Notably, the researchers emphasize that this approach does not completely shut down the immune system but instead fine tunes its activity to prevent harmful overactivation. This is important because a fully suppressed immune response could leave the brain vulnerable to infections and impair normal repair mechanisms.
The team is now working to develop small molecule drugs that can specifically block this modification site on STING. Advances in targeted drug design and structure-based therapeutics may accelerate this process, although further validation in human studies will be required. If successful, these therapies could move into preclinical development and eventually clinical trials.
The findings add to a growing body of evidence that controlling inflammation in the brain could be a powerful strategy for combating Alzheimer’s disease and potentially other neurodegenerative disorders. As research continues to shift toward multi target approaches, combining anti inflammatory strategies with therapies aimed at protein aggregation may offer the best hope for modifying disease progression.
Reference
- Carnevale LN, Banerjee P, Zhang X, Navarro J, Raspur CK, Patel P, et al. Redox regulation of neuroinflammatory pathways contributes to damage in Alzheimer’s disease brain. Cell Chemical Biology. 2026 Apr 23;0(0).